| Document |
Document Title |
|
WO/2002/036533A1 |
Monomers having electron-withdrawing groups, as represented by the general formula (a), (b) or (c), wherein A?1¿, A?2¿, and A?3¿ are each a ring; R?a¿, R?b¿, R?c¿, and R?u¿ are each independently hydrogen or an organic group; at l...
|
|
WO/2002/036641A2 |
Improved Group 3-11 transition metal based catalysts and processes for the polymerization of olefins are described. Some of the ligands are characterized by a preferred substitution pattern which allows for higher productivities of highl...
|
|
WO/2002/034740A1 |
The invention relates to a method for producing cyclic carboxylic orthoester fluorides, comprising the following steps: a) reacting at least one bis(alkylthio)carbenium salt in the presence of at least one base with at least one organic ...
|
|
WO/2002/032377A2 |
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for t...
|
|
WO/2002/030919A1 |
Process for the synthesis of R(+)$g(a)-lipoic acid comprising the following stages: a) Salifying of racemic 6,8-halo-octanoic acid with S(-)$g(a)-methylbenzylamine; b) separation by filtration of the crystallized diastereoisomeric salt o...
|
|
WO/2002/030918A2 |
Process for the synthesis of R(+)$g(a)-lipoic acid comprising the following stages: a) Salifying of racemic thioctic acid with R(+)$g(a)-methylbenzylamine; b) separation by filtration of the crystallized diastereoisomeric salt of R(+)$g(...
|
|
WO/2002/030917A2 |
Process for the synthesis of racemic thiotic acid comprising the following stages: a) reaction of the alkyl ester of 6,8-di-halo-octanoic acid in an organic solvent with an aqueous solution of alkali disulfide in presence of a compound f...
|
|
WO/2002/026909A1 |
Compositions and methods for using these compositions to produce high yields of thionated compounds are provided.
|
|
WO/2002/024613A2 |
The present invention relates to certain resorcinol derivatives and their use as skin lightening agents.
|
|
WO/2002/022694A1 |
Catalyst compositions useful for the polymerization of olefins are disclosed. These compositions comprise a Group 8-10 metal complex comprising a bidentate or variable denticity ligand comprising two nitrogen donor atoms independently su...
|
|
WO/2002/010151A2 |
The invention relates to a method for producing R-lipoic acid and S-lipoic acid comprising a step selected from the following: (a) distillation of dihydrolipoic acid, (b) reaction of (2) or the stereoisomer thereof, wherein Ms represents...
|
|
WO/2002/010113A1 |
The invention relates to a method for producing compounds of general formula (I) wherein R?1¿ represents a C¿1?-C¿20? alkyl group, a C¿3?-C¿12? cycloalkylgroup, a C¿7?-C¿12? aralkyl group, or a mono or bicyclic aryl group. A keton...
|
|
WO/2002/002533A1 |
Medicinal compositions, in particular, GnRH receptor antagonists comprising propane-1,3-dione derivatives represented by the following general formula (1) as the active ingredient; and novel propane-1,3-dione derivatives having a GnRH an...
|
|
WO/2001/093824A1 |
The present invention relates to the use of lipoic acid, lipoic acid derivatives or salts thereof having an (R)-enantiomer-excess in cosmetic compositions for skin or hair and for the preparation of dermatological compositions for the tr...
|
|
WO/2001/093865A2 |
The invention relates to the use of $g(a)-lipoic acid in reduced or oxidised form, or derivatives thereof which have an intact dithiolane structure in the form of enantiomers, or pharmaceutically acceptable salts, amides, esters, thioest...
|
|
WO/2001/092252A1 |
A sulfurized (meth)acrylic ester compound represented by the formula (1) (wherein R¿1? and R¿2? each represents hydrogen or alkyl and may be bonded to each other to form a ring; R¿3? represents hydrogen or methyl; X¿1? represents oxy...
|
|
WO/2001/085165A2 |
The invention relates to the use of lipoic acid and C¿1? donors, especially S-adenosylmethionine and/or 5-methyltetrahydrofolate, for treating disorders of the central nervous system. The invention also relates to agents containing a co...
|
|
WO/2001/085677A1 |
The invention concerns novel amino acid derivatives and their use as medicines. Said derivatives have an inhibiting activity towards NO-synthase enzymes producing nitrogen monoxide NO and/or (optionally): either an activity trapping reac...
|
|
WO/2001/083571A2 |
Catalyst compositions useful for the polymerization or oligomerization of olefins are disclosed. Certain of the catalyst compositions comprise N-pyrrolyl substituted nitrogen donors. Also disclosed are processes for the polymerization or...
|
|
WO/2001/080856A2 |
The invention concerns the use of anethole-dithiolethione for producing a medicine for preventing drug-induced tendon toxicity.
|
|
WO/2001/068575A1 |
A cation or acid generator which, upon irradiation with energy rays, can generate cations or an acid with high sensitivity and which is suitable for use in chemical amplification type resist materials. It comprises an energy-ray-sensitiv...
|
|
WO/2001/068643A2 |
The invention concerns novel heterocyclic or benzene derivatives comprising a lateral chain derived from lipoic acid, having an activity inhibiting NO-synthase enzymes producing NO nitrogen monoxide and/or are agents enabling regeneratio...
|
|
WO/2001/064667A1 |
The invention relates to a method for producing compounds that have at least one -CF¿2?-O bond in the molecule by reacting a bis(alkylthio) carbenium salt in the presence of a base with a compound that contains at least one hydroxy grou...
|
|
WO/2001/049250A2 |
Active acne and acneiform scars are treated by topical application of a composition containing lipoic acid and/or a lipoic acid derivative such as dihydrolipoic acid, a lipoic or dihydrolipoic acid ester, a lipoic or dihydrolipoic acid a...
|
|
WO/2001/049275A2 |
Methods and therapeutic compounds for treating pain, mitigating inflammation, effecting analgesia and/or effecting sedation in a subject are described. A subject is administered an effective amount of a therapeutic compound which is a ni...
|
|
WO/2001/047911A1 |
The invention concerns cationic amphiphiles derived from lipoic acid, their uses as DNA transfection vectors and their synthesis method.
|
|
WO/2001/040175A1 |
A process for producing a sulfur compound bearing at least one thio group in the molecule by reacting a thiol compound with an organic compound bearing at least one functional group capable of reacting with a mercapto group to thereby fo...
|
|
WO/2001/040874A1 |
The use of a compound of formula (A), which comprises a group of sub-formula (I) where R?1¿, R?2¿, R?3¿, R?4¿, R?5¿, R?6¿, X?1¿ and Y?1¿ are various specified organic groups wherein at least one of said groups has sufficient elec...
|
|
WO/2001/025226A1 |
The present invention describes methods for synthesizing novel dithiolane derivatives, ligands with high affinity for the nuclear hormone receptors, peroxisome proliferator-activated receptor-$g(g)(PPAR$g(g)) and/or PPAR$g(a). Methods fo...
|
|
WO/2001/019341A1 |
The invention relates to a process of modification of the nitrogen oxides metabolism by means of modification of the micellar catalysis parameters of NO oxidation. According to the invention, the number of phases and/or the volume ratio ...
|
|
WO/2001/015693A2 |
The invention relates to the use of racemic $g(a)-lipoic acid, or its enantiomers or pharmaceutically acceptable salts, amides, esters or thioesters thereof in reduced or oxidised form, as an active ingredient for the prevention or treat...
|
|
WO1999057111A9 |
The invention relates to cyclohexenondioxothiochromanoyl derivatives of formula (I) wherein the variables have the following meanings: X is oxygen, sulphur, S=O, S(=O)2, CR<4>R<5>, C=O or C=NR<6>; R<1> is hydrogen, nitro, halogen, cyano,...
|
|
WO/2001/012620A1 |
The invention relates to a method used for the production of a solvent-free a-liponic acid, wherein: a) the $g(a)-linoleic acid which is to be purified is dissolved in an aqueous alkaline solution or the salt thereof in water, and the pH...
|
|
WO/2001/009118A2 |
The invention provides methods to treat neurological disorders such as Alzheimer's disease, or to slow the progression of such diseases, or to treat and/or prevent other disorders as disclosed in the specification, by administering to pa...
|
|
WO/2000/071533A2 |
The invention is directed to 1,4-dithiin- and 1,4-dithiepin- 1,1,4,4-tetroxide derivatives useful as galanin receptor antagonists for treating disorders of the central nervous system. Pharmaceutical compositions comprising the compounds ...
|
|
WO/2000/069810A1 |
A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or preventio...
|
|
WO/2000/059899A1 |
The invention concerns novel lipoic acid derivatives, which have an inhibiting action with respect to NO-synthase enzymes producing nitrogen monoxide NO and/or are agents enabling the regeneration of antioxidants or entities trapping rea...
|
|
WO/2000/058258A1 |
Compounds which are useful in the efficient synthesis of 2-amino-4-oxobicyclo[3.1.0]hexane-2,6-dicarboxylic acid. The compounds are 2-oxobicyclo[3.1.0]hexane-6-carboxylic acid derivatives represented by formula (1) [wherein R?1¿ represe...
|
|
WO/2000/054756A2 |
Compounds and methods for mitigating neurodegeneration, effecting neuroprotection and/or effecting cognition enhancement in a subject are described. Neurological or cognitive conditions are treated by administering to a subject an effect...
|
|
WO/2000/052530A1 |
Radically photopolymerizable compositions comprising (a) at least one ethylenically unsaturated photopolymerizable compound; (b) as photoinitiator, at least one compound of formulae (I, II, III, IV, V and/or VI), wherein m is 0 or 1; n i...
|
|
WO/2000/044731A1 |
The current invention discloses novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors. Compounds of particular interest are defined by Formula (I) wherein X, Y, A, J, R?1¿, R?2¿ R?3¿, R?4¿, R?7¿ and...
|
|
WO/2000/040576A2 |
A compound of formula (I) in which R?1¿ is lower alkyl, halogen, optionally substituted heterocyclic group or optionally substituted aryl, R?2¿ is carboxy, protected carboxy or amidated carboxy, Ar is optionally substituted aryl or opt...
|
|
WO/2000/035903A2 |
The invention relates to thiochromanoyl cyclohexenone derivatives of formula (I), wherein the variables have the following meanings: A is an optionally substituted, saturated or unsaturated alkyl chain; R?1¿ is cyano, rhodano, nitro, OR...
|
|
WO/2000/034348A1 |
Cationic polymerization initiators of formula (I) are disclosed. The acyl sulfonium salts of the present invention differ from known acyl sulfonium initiators in that the substituents R?2¿ and R?3¿ on the sulfur are larger and more com...
|
|
WO/2000/031060A1 |
The present invention provides novel compounds having scavenging and anti-ROS properties and pharmaceutical composition comprising these compounds for treatment of conditions associated with oxidative stress or free radical injury. The c...
|
|
WO/2000/031072A1 |
This invention relates to a novel process of preparing selected 5-substituted pyrazoles useful as p38 kinase and COX-2 inhibitors.
|
|
WO/2000/024734A1 |
This invention relates to the identification of a novel class of therapeutic agents which selectively target and kill tumor cells and certain other types of diseased cells, and to compositions comprising lipoic acid derivatives which poi...
|
|
WO/2000/012464A1 |
Fluorobicyclo[3.1.0]hexane derivatives represented by general formula (I), pharmaceutically acceptable salts thereof or hydrates of the same wherein R?1¿ and R?2¿ represent each hydrogen, alkyl, cycloalkyl, etc.; and Y?1¿ and Y?2¿ re...
|
|
WO/2000/008012A1 |
The invention relates to enantiomer-free crystalline (R) or (S) lipoic acid, where the reflection line at 2 $g(U) = 23° is the most intensive one in the 13° to 30° range in the 2 $g(U) diffractogram.
|
|
WO/2000/004892A2 |
This invention is the coadministration of ACAT and MMP inhibitors for the reduction of both the macrophage and smooth muscle cell component of atherosclerotic lesions, thus impairing the expansion of existing lesions and the development ...
|
